🟢 Novanta is trading 8.2% up in pre-market after Q2 results and raised full-year revenue guidance

Novanta is trading 8.2% up at $180.01 after investors continued reacting to its August 5 second-quarter earnings release.

• Revenue reached $265.8 million, adjusted EPS was $0.89, and management raised full-year revenue guidance to $1.13 billion-$1.14 billion.
• The recently closed Riverpoint Medical acquisition is expected to immediately boost revenue, margins, and earnings while doubling recurring medical-consumables revenue.
• Broader market support is modest, making company-specific earnings and acquisition outlook the primary catalyst.